Narbonne

Researchers are investigating the relationship between tongue color features and anxiety-depression levels in patients receiving acupuncture. This study uses the Montgomery-Åsberg Depression Rating Scale (MADRS) to measure anxiety and depression severity and aims to identify correlations through machine learning analysis. The goal is to explore a non-invasive diagnostic method that could aid in assessing psychological conditions in clinical practice. Participants will have their tongue photographed using an iPhone camera under standardized lighting and positioning to ensure consistent image quality. Alongside this, they will complete the MADRS questionnaire during their routine acupuncture consultation. No changes to usual treatment or invasive procedures are involved in this observational study. The collected tongue images and questionnaire data will be analyzed with machine learning algorithms to find patterns linking tongue color features to anxiety and depression scores. This approach uses common smartphone technology to promote easy replication and accessibility. The study focuses on early detection and monitoring of anxiety-depressive disorders to improve personalized care in complementary medicine.

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study to see if it can reduce the risk of major adverse cardiovascular events (MACE-PLUS) in adults with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for a first ASCVD event. The study compares AZD0780 to a placebo and monitors participants from randomization until the primary analysis censoring date, followed by a final study closure visit. Participants will be randomly assigned to receive either oral AZD0780 or an oral placebo once daily. The treatment period lasts until the primary analysis censoring date, after which a study closure visit will occur. The study is event-driven and designed to assess the time to the first major cardiovascular event during treatment. During the study, participants will be closely monitored with various assessments to evaluate cardiovascular outcomes and safety over approximately 54 months. Researchers will track the time to first event of any component of MACE-PLUS and collect data to assess the effect of AZD0780 compared to placebo. The study includes regular visits and evaluations to ensure participant safety and adherence to treatment.

The trial investigates spinal conditions such as spinal stenosis and spondylolisthesis, focusing on reducing the need for lumbar fusion surgery. It evaluates the use of endoscopic techniques for decompressing the lumbar spine, aiming to preserve its natural stability and function. This approach is considered a less invasive alternative to traditional surgical methods, with the hypothesis that it can lower the frequency of more extensive spinal fusion procedures. The study centers on endoscopic decompression procedures as a treatment option for patients with specific lumbar spine pathologies. These minimally invasive surgeries are designed to be optimized and cause less tissue damage. Participants are patients who have spinal conditions requiring surgical intervention, including those with complications such as lumbar scoliosis or degenerative spondylolisthesis. The endoscopic approach is assessed as a potentially effective way to avoid lumbar arthrodesis. Participants will be monitored primarily for the need for any additional surgical interventions within one year after treatment. The study involves evaluations using preoperative imaging, such as radiographs and MRI, to classify spinal abnormalities and determine eligibility. Safety and outcomes are tracked over the course of a year to understand the effectiveness of the endoscopic procedures in reducing the requirement for further surgery.

Researchers are evaluating the effectiveness and safety of sonelokimab compared with placebo in adults with active psoriatic arthritis who have not responded well or could not tolerate anti-tumor necrosis factor alpha (TNFb1) therapy. This Phase 3, randomized, double-blind study also includes risankizumab as an active reference treatment to better understand the benefits and risks of sonelokimab for this condition. Participants will be randomly assigned to one of four groups receiving either sonelokimab at doses of 60 mg or 120 mg, placebo, or risankizumab. The treatments are given by injection under the skin. The study is conducted across multiple centers and compares the response rates after 16 weeks of treatment to evaluate improvement in psoriatic arthritis symptoms. During the trial, participants will undergo joint assessments, blood tests for specific antibodies, and evaluations of skin psoriasis. Researchers will monitor how many participants achieve at least a 50% improvement in arthritis criteria compared to placebo. Safety and side effects will be closely observed throughout the study. The total time involved includes screening, treatment, and follow-up visits to ensure thorough evaluation of both effectiveness and safety.

Researchers are evaluating the use of a capillary medical device to measure C-reactive protein (CRP) in children with fever aged between 0.25 months and 15 years. Fever is a common reason for outpatient visits among children, and distinguishing between viral and bacterial infections can be challenging. Since current CRP test results take several hours and cause delays in treatment, this study aims to assess whether rapid CRP measurement in primary care can reduce unnecessary referrals to emergency laboratories and ease overcrowding in emergency rooms and clinics. The study involves using the ACTIM-CRP device for semi-quantitative measurement of capillary CRP levels in febrile children during primary care visits. Children with fever meeting specific criteria related to fever duration and concern for bacterial infection are included. The intervention is designed to streamline the care pathway for these children by providing faster test results directly in primary care settings. Participants will be monitored for referral rates to facilities equipped for emergency laboratory testing on Day 1 and Day 7 after the initial consultation. The study also tracks treatment decisions and the impact on healthcare utilization. Parents and children will be informed about the study, and consent will be obtained. The overall goal is to improve fever management in children and reduce unnecessary emergency visits, benefiting both families and healthcare systems.

Researchers are evaluating the effects of baxdrostat combined with dapagliflozin compared to dapagliflozin alone in adults aged 40 and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with systolic blood pressure of at least 130 mmHg at screening, and at least one additional risk factor for heart failure. This Phase III randomized, placebo-controlled, event-driven study aims to determine if the combination reduces the risk of heart failure events or cardiovascular death, with follow-up lasting up to 38 months. Participants who meet screening criteria but are not currently treated with SGLT2 inhibitors or have been treated for less than 4 weeks will enter a run-in period receiving dapagliflozin 10 mg once daily for 4 to 6 weeks before randomization. The study involves random assignment to either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Site visits occur at approximately 2, 4, 8, 16, and 34 weeks after randomization, then every 4 months. Participants discontinuing the blinded study drug may continue open-label dapagliflozin, with ongoing visits and data collection as per protocol. Participants will undergo an optional pre-screening period without site visits or consent to help identify eligibility, followed by up to 14 days of formal screening after informed consent. Researchers will monitor heart failure events and cardiovascular deaths as primary outcomes. Safety and adherence will be tracked throughout the study, including during any premature discontinuation of blinded treatment. The study will conclude when a predetermined number of secondary endpoint events have occurred, with continued follow-up as needed.

Thrombotic Micro-angiopathy (TMA) is a serious condition that includes Haemolytic and Uraemic Syndrome (HUS), requiring quick diagnosis and treatment. This study evaluates a therapeutic orientation test designed to detect the involvement of the complement system in TMA diagnosis. The test measures complement deposits on endothelial cells in a lab setting and aims to improve early detection of complement activation, which is important for timely treatment with drugs like Eculizumab that block the complement pathway. The therapeutic orientation test is performed on blood samples collected at three points: at the start of the study, at one month, and at six months. The study compares the test results with patients' clinical outcomes and the presence of abnormalities in complement regulation. This approach helps to assess the test's sensitivity and specificity over an average follow-up period of three years. Participants will undergo diagnostic testing and clinical monitoring throughout the study. Researchers will evaluate how well the test predicts complement involvement and patient evolution, especially in relation to treatment with Eculizumab. The study will use blood tests and clinical data to measure outcomes, tracking participants' health over several years to determine the test’s accuracy and usefulness in managing TMA.